Structure-based computational screening of cyclotides as putative CYP19A1-binding scaffolds for modulation of estrogen biosynthesis in adenomyosis

Other OA: gold public-domain-us

Abstract

Adenomyosis is a chronic estrogen-dependent gynecological disorder associated with dysmenorrhea, abnormal uterine bleeding, chronic pelvic pain, infertility, and recurrent implantation failure. Because human placental aromatase cytochrome P450 (CYP19A1) plays a central role in local estrogen biosynthesis, this study employed an integrated in silico workflow to identify cyclotide scaffolds capable of interacting with CYP19A1. The receptor structure was prepared and validated, while protein-protein interaction analysis confirmed its involvement in steroidogenesis and estrogen biosynthesis. Twenty cyclotides were modeled and screened against the predicted active site of CYP19A1. Based on an integrated evaluation of HADDOCK and ClusPro docking, binding orientation, and interaction characteristics, cycloviolacin O4 was prioritized as the lead candidate. The predicted CYP19A1-cycloviolacin O4 complex exhibited a HADDOCK score of -82.8 ± 9.8, a cluster RMSD of 0.2 ± 0.1 Å, and a ClusPro energy score of -872.1. Docking against the reference inhibitor exemestane and the reference peptide SNA-60-367-10 provided additional computational benchmarking. Subsequent 500 ns molecular dynamics simulations, normal mode analysis, and MM-GBSA/MM-PBSA calculations supported the predicted structural stability and dynamic compatibility of the complex, yielding binding free energies of -66.58 ± 3.46 kcal/mol (MM-GBSA) and -4.56 ± 4.29 kcal/mol (MM-PBSA). Computational safety assessment predicted cycloviolacin O4 to be non-antigenic, non-allergenic, and non-toxic, while immune simulation suggested a balanced immune response. Collectively, these findings identify cycloviolacin O4 as a computationally predicted CYP19A1-binding cyclotide scaffold. However, these observations are derived exclusively from computational analyses and require biochemical, cellular, and in vivo validation before any conclusions regarding biological activity or therapeutic potential can be drawn.

My notes (saved in your browser only)

MeSH descriptors

Adenomyosis Adenomyosis Adenomyosis Aromatase Aromatase Aromatase Aromatase Cyclotides Cyclotides Cyclotides Cyclotides Estrogens Estrogens Estrogens Amino Acid Sequence Amino Acid Sequence Binding Sites Binding Sites Female Female

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (48)

Source provenance

europepmc
last seen: 2026-11-19T06:13:19.037553+00:00
openalex
last seen: 2026-11-19T06:04:33.792782+00:00
pubmed
last seen: 2026-11-19T06:06:24.241706+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine